Business
Neural Therapeutics Announces CSE Application to Acquire Full Ownership of Hanf.com, Shareholder Meeting, SIO Agreement Amendment and Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers.Ronnie Jaegermann, Chief Executive Officer of CWE, stated: "Hanf.com has established a strong position in...
About this update from Neural Therapeutics Inc.
[{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers.","length":433,"tagName":"p"},{"type":"text","content":"Ronnie Jaegermann, Chief Executive Officer of CWE, stated: "Hanf.com has established a strong position in Germany's regulated CBD and hemp market over the past five years. We believe full integration with Neural, if completed, would provide enhanced access to capital markets and additional strategic flexibility to accelerate retail expansion and brand development. We remain focused on disciplined growth and operational execution as we continue to build one of Germany's leading specialty CBD retail platforms."","length":532,"tagName":"p"},{"type":"text","content":"John Durfy, Chairman of the Board of Directors at Neural, added, "Completing this transaction is the final step in transforming Neural from a pure R&D focused organization into a commercially operating entity with strong fundamentals, rapid revenue growth and profitable operations. We believe the final step of the transaction with CWE will continue to generate shareholder value and we look forward to reporting on our progress as we are driving towards closing."","length":479,"tagName":"p"},{"type":"text","content":"CSE Application and Series B Transactions","length":41,"tagName":"p"},{"type":"text","content":"Pursuant to the strategic investment and option agreement dated May 26, 2025 (the "SIO Agreement"), Neural holds the right, but not the obligation, to acquire the remaining 69.25% interest in CWE (the "Series B Option"). If exercised, the Series B Option would result in Neural acquiring 100% of CWE (the "Series B Transactions"). The terms of the Series B Option and Series B Transactions are outlined in more detail in the SIO Agreement (and the amendment thereto) will be available under Neural's profile on www.sedarplus.ca, and are summarized in Neural press releases dated May 28, 2025 and August 13, 2025.","length":646,"...